"Our strategy of filing additional Continuation-In
Post# of 9122
(Total Views: 502)
Posted On: 04/13/2021 12:11:15 AM
Re: nmbr1stckpckr #8136
"Our strategy of filing additional Continuation-In-Part patent applications for the ongoing research for SARS2/COVID19 Rapid Viral Assay development taking place between NanoLogix and several critical partners is projected to continue. These entities include a diagnostic company, a research team at a significant university, and a developing collaboration with a highly regarded research organization."
Looks like the Company has expanded the number of organizations they are working with. I wonder who the 'diagnostic company' is. Nanologix is a diagnostic company so...hmmm.....I'm FOMO guessing here, but sounds like NNLX hooked a big fish on their RVA baited line!
Looks like the Company has expanded the number of organizations they are working with. I wonder who the 'diagnostic company' is. Nanologix is a diagnostic company so...hmmm.....I'm FOMO guessing here, but sounds like NNLX hooked a big fish on their RVA baited line!
(0)
(1)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼